Flt3 Does Not Play a Critical Role in Murine Myeloid Leukemias Induced by MLL Fusion Genes

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Albouhair, Stéphanie ^a,b   Morgado, Ester ^a   Lavau, Catherine ^a,c  

^a CNRS   (France)

^b PAREXEL INTERNATIONAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MIDOSTAURIN; 4'-N-BENZOYLSTAUROSPORINE; FLT3 PROTEIN, MOUSE; HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; FLT3 GENE; FUSION GENE; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; BONE MARROW TRANSPLANTATION; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MYELOID PROGENITOR CELL; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE-LYSINE N-METHYLTRANSFERASE; LEUKEMIA, MYELOID; MICE; MICE, KNOCKOUT; MYELOID PROGENITOR CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAUROSPORINE;

EID: 84881599676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072261     Document Type: Article

References (28)

1. Eguchi M, Eguchi-Ishimae M, Greaves M, (2003) The role of the MLL gene in infant leukemia. Int J Hematol 78: 390-401.
2. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41-47.
3. Kohlmann A, Schoch C, Dugas M, Schnittger S, Hiddemann W, et al. (2005) New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 19: 953-964.
4. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, et al. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104: 3679-3687.
5. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143.
6. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL, (2005) Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 65: 11367-11374.
7. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183.
8. Rozovskaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, et al. (2003) Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements. Proc Natl Acad Sci U S A 100: 7853-7858.
9. Tsutsumi S, Taketani T, Nishimura K, Ge X, Taki T, et al. (2003) Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 63: 4882-4887.
10. Wang GG, Pasillas MP, Kamps MP, (2006) Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. Mol Cell Biol 26: 3902-3916.
11. Jiang X, Huang H, Li Z, Li Y, Wang X, et al. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 22: 524-535.
12. Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, et al. (2004) FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103: 267-274.
13. Kindler T, Lipka DB, Fischer T, (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089-5102.
14. Brown P, Levis M, Shurtleff S, Campana D, Downing J, et al. (2005) FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105: 812-820.
15. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, et al. (2005) Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106: 2484-2490.
16. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK, (2010) Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 151: 295-311.
17. Morgado E, Albouhair S, Lavau C, (2007) Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. Blood 109: 4020-4022.
18. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, et al. (2008) MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 22: 66-77.
19. Lavau C, Du C, Thirman MJ, Zeleznik-Le N, (2000) Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 17: 4655-4664.
20. Lavau C, Luo RT, Du C, Thirman MJ, (2000) Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A 97: 10984-10989.
21. Su X, Drabkin H, Clappier E, Morgado E, Busson M, et al. (2006) Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. Genes Chromosomes Cancer 45: 846-855.
22. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, et al. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3: 147-161.
23. Lavau C, Szilvassy S, Slany R, Cleary ML, (1997) Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally-transduced HRX-ENL. EMBO J 16: 4226-4237.
24. Forster A, Pannell R, Drynan LF, McCormack M, Collins EC, et al. (2003) Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3: 449-458.
25. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, et al. (2005) Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. Embo J 24: 368-381.
26. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, et al. (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88: 2004-2012.
27. Levis M, Brown P, Smith BD, Stine A, Pham R, et al. (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108: 3477-3483.
28. Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, et al. (2005) Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci U S A 102: 19069-19074.